Guest guest Posted September 1, 2010 Report Share Posted September 1, 2010 Dear Group, I know there is someone in this group who is in the DCC 2036 trial. MDACC called me today and invited me to join in this trial. Phase II is opening up and there are 2 slots left open. The person I am referring to is the one who posted that her FISH results were always 50%. Would you kindly reply ASAP and give me more information before I make up my mind one way or the other to let them know if I will accept the offer. Reply to me personally so that I may get the information sooner than waiting for the list to be emailed. Thanx, Lottie Duthu " DCC-2036 is a novel TKI that overcomes imatinib resistance by binding to a different domain on the BCR-ABL protein, thus avoiding interaction with the mutated regions most commonly associated with resistance, particularly the T315I mutation. DCC-2036 is given orally either daily or twice daily continuously. The dose escalation phase of the study is ongoing. " http://www.mdanderson.org/publications/leukemia-insights/issues/spring-2010/inhi\ bitors.html Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.